The outbreak of COVID-19 has raised global concerns regarding the new coronavirus SARS-CoV-2 that is known to infect humans causing severe pneumonia and even death. This epidemic disease is threatening the global health, and therefore, demands on fast diagnostic methods or IVD kits from international hospitals far exceed supply. To fix this challenging issue, scientists that are specialized in the development of immunoassays of different formats at Creative Biolabs are ready, where IVD kit or assay development services are backed by years of experience, with hundreds of immunoassay kits successfully developed, manufactured, and distributed to continents around the world.
All the clients developing enzyme linked immune sorbent assay (ELISA), radioimmunoAssay (RIA), lateral-flow immunochromatographic assay (LFIA), latex particle-enhanced turbidimetric immunoassay (LETIA), western blot and so on can obtain the most sensitive, reproducible immunoassays and immunodiagnostic kits that are differentiated from high-performance formulations for quicker commercialization.
ELISA Based Kit Development
Holding properties like high sensitivity & specificity, accuracy and applicability, enzyme linked immune sorbent assay is taken as one of the most universally applied protein detection technologies. Clients can find various signal-transducer principle based kit development solutions, including colorimetric immunoassay (CIA) based kits development, chemiluminescent immunoassays (CLIA) based kits development, electrochemiluminescence immunoassay (ECLIA) based kits development, protein microarray based kits development, etc., which are supported by the newly developed antibodies & antigens and high-end facilities to ensure detection accuracy of your ELISA tests.
RIA Based Kits Development
Radioimmunoassay is conventionally seen in many labs around the world because of its ability to detect molecules in complicated matrics and high specificity of antigen-antibody reaction. It can analyze nanomolar and picomolar concentrations of blood, tissues, and other biologic fluids of peptidal and non-peptide hormones, enzymes, drugs, viruses, bacterial antigens, and other organic substances. Creative Biolabs has produced RIA-based kits that can accomplish quantitative measurement of the target amongst million-fold excess of other complexes.
“All of the kit development services will be operated based upon our IVD antibody development platforms,” according to a scientist at Creative Biolabs, “and we are always optimizing to make them up-to-date.” The typical workflow falls in three phases, project scoping, assay development, and production & manufacture, which can operate at fast speed and low cost.
More information is accessible at https://www.creative-biolabs.com/drug-discovery/diagnostics.
About Creative Biolabs
Founded in 2004, talented and well-trained scientists at Creative Biolabs are working mutually to achieve the goal of global customers. To explore and develop the qualified medicines of tomorrow, Creative Biolabs’s scientists are concentrating on every important aspect of the industry, especially for the drug discovery pipeline, making itself one of the few companies that can offer integrated drug discovery services. Services compose target identification and validation, hit identification, hit to lead, lead optimization to the investigational new drug (IND), which are classified according to different diseases or themes.
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Country: United States